Foghorn tumbles after FDA puts cancer drug trial on partial hold
19/05/2022 21:52
** Biopharma co's shares FHTX.O fall 25.7% to $8.50 in
extended trading
** Co says the U.S. FDA has put an early-stage study of its
experimental cancer therapy on partial clinical hold, following
a report of a recent death urn:newsml:reuters.com:*:nFWN2XB0WO
** FDA has requested a review of co's safety database, risk
mitigation strategies and breakdown of clinical activity across
dose levels
** The trial was testing FHD-286 in blood-related cancers
** Stock down ~50% YTD
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))